Hemorrhagic Cystitis
📧 Sign up to get email alerts when something new happens for Hemorrhagic Cystitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT [NA]
A clinical trial is currently recruiting to evaluate moxibustion for preventing hemorrhagic cystitis after allogeneic hematopoietic stem cel…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis [Phase 2]
Phase 2 clinical trial comparing cidofovir to best supportive care for hemorrhagic cystitis in transplant recipients; the study is active bu…
-
FDA approval · 2025-01-13FDA Approved: MESNA — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved the original application for MESNA (Ingenus Pharmaceuticals, LLC) to reduce the risk of chemotherapy-related hemorrhagic cystit…
-
CLINICAL_TRIALS research · 2024-12-12Clinical Trial Update: Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation
A recruiting clinical trial evaluating the efficacy and patient experience of a catheter-free intravesical instillation approach for various…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT [NA]
A clinical trial is evaluating moxibustion for treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. The s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-07-17FDA Approved: MESNA — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for MESNA submitted by Hikma Pharmaceuticals USA Inc., likely expanding or updating its labeling.
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) [Phase 3]
Phase 3 study evaluating Viralym-M (ALVR105) for virus-associated hemorrhagic cystitis, including BK virus infection, was terminated with re…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, and efficacy of LP-10 in adults with refractory moderate to severe hemorrhagic cysti…
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs [Phase 2]
Phase 2 trial update on chlorophyllin tablets for urinary bleeding after radiation therapy for pelvic organ cancers (hemorrhagic cystitis).
-
FDA approval · 2019-09-15FDA Approved: MESNA — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for MESNA submitted by Fresenius Kabi USA, LLC.
-
FDA approval · 2019-09-06FDA Approved: MESNA — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for MESNA Injection from Gland Pharma Limited, validating its manufacture and labeling for this gene…
-
FDA approval · 2018-12-17FDA Approved: MESNA — Supplemental Application (Baxter Healthcare Company)
FDA approved a supplemental application for MESNA submitted by Baxter Healthcare Company. This approval updates the approval status of MESNA…
-
FDA approval · 2018-12-17FDA Approved: MESNEX — Supplemental Application (Baxter Healthcare Company)
The FDA approved a supplemental application for MESNEX (mesna) from Baxter Healthcare Company. The action relates to the approved use of MES…
-
FDA approval · 2017-12-18FDA Approved: MESNA — Original Application (Gland Pharma Limited)
FDA approved an Original Application for MESNA injection from Gland Pharma Limited. MESNA is used to prevent chemotherapy-induced hemorrhagi…
-
CLINICAL_TRIALS trial_result · 2017-01-12Clinical Trial Update: Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis [Phase 2]
Phase 2 study evaluating the efficacy and safety of activated recombinant human factor VII in patients with refractory hemorrhagic cystitis.
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: Intravesical Cidofovir for Hemorrhagic Cystitis [Phase 1]
This update reports the completion of a Phase 1 trial evaluating intravesical cidofovir for hemorrhagic cystitis in patients undergoing bloo…
-
FDA approval · 2016-02-26FDA Approved: MESNA — Supplemental Application (Baxter Healthcare Company)
The FDA approved a supplemental application for MESNA submitted by Baxter Healthcare Company. The action updates MESNA's labeling under the …
-
FDA approval · 2015-11-18FDA Approved: MESNA — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for MESNA submitted by Fresenius Kabi USA, LLC (ANDA 075811). This approval updates the regulato…
-
FDA approval · 2015-08-21FDA Approved: MESNA — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for MESNA submitted by Sagent Pharmaceuticals, resulting in an approved change to the product’s labe…
-
CLINICAL_TRIALS trial_result · 2014-06-25Clinical Trial Update: A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis [Phase 2]
Phase 2 clinical trial update evaluating placenta-derived decidual stromal cells for hemorrhagic cystitis in stem cell transplant patients; …
-
CLINICAL_TRIALS trial_result · 2014-06-24Clinical Trial Update: A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating placenta-derived decidual stromal cells for hemorrhagic cystitis has completed.
-
FDA approval · 2014-03-17FDA Approved: MESNEX — Supplemental Application (Baxter Healthcare Company)
FDA approved a supplemental application for MESNEX (mesna) submitted by Baxter Healthcare Company.
-
FDA approval · 2014-03-17FDA Approved: MESNA — Supplemental Application (Baxter Healthcare Company)
The FDA approved a supplemental application for MESNA by Baxter Healthcare Company.
-
FDA approval · 2012-12-28FDA Approved: MESNEX — Supplemental Application (Baxter Healthcare Company)
The FDA approved a supplemental application for MESNEX (mesna) from Baxter Healthcare Company.
-
FDA approval · 2010-04-13FDA Approved: MESNA — Original Application (Sagent Pharmaceuticals)
FDA approved MESNA (Sagent Pharmaceuticals) through an Original Application/ANDA to protect against chemotherapy-induced hemorrhagic cystiti…